

Kazia Therapeutics Ltd

03:46 20 May 2019

Kazia Therapeutics to collaborate with US-based oncology foundation on clinical trials for metastatic brain cancer treatment

Kazia Therapeutics Ltd (ASX:KZA) has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance) to launch a multi-centre phase-two study investigating the potential use of Kazia's GDC-0084 drug in treating brain metastases.

The US-based cancer research network is sponsored by the National Cancer Institute and will also investigate several other targeted cancer therapies.

Kazia chief executive officer James Garner said the Alliance study was a ground-breaking research project that aims to investigate several experimental drugs in a single clinical study.

He said: "Patients will be allocated to treatment depending on their tumour's individual genetic signature and patients with a mutation affecting the PI3K pathway will be eligible to receive GDC-0084.

"This kind of approach is very much the future of cancer treatment."

READ: Kazia Therapeutics' ongoing study confirms higher drug tolerability in newly-diagnosed glioblastoma

Alliance is to initiate the open-label phase-two study which will allocate to patients either abemaciclib (Eli Lilly), entrectinib (Genentech) or Kazia's GDC-0084, based on the genetic profile of their tumour.

The trial is expected to recruit up to 150 patients across multiple US medical centres and Kazia will support it by providing the study drug and a financial grant.

Only patients with a genetic alteration in the PI3K pathway will receive GDC-0084, which is expected to comprise about one-third of total patients recruited.

Patients with other genetic mutations will receive either CDK inhibitor abemaciclib, approved by the Federal Drug Administration (FDA) for treatment of certain forms of breast cancer, or Trk/ALK inhibitor entrectinib which has not yet been approved by the FDA.

READ: Kazia Therapeutics' studies evaluate therapeutic candidates in ovarian cancer and brain tumours

Harvard Medical School Assistant Professor of Medicine and principal investigator of the study Priscilla Brastianos said brain metastases represented

Price: 0.4

Market Cap: \$28.87 m

1 Year Share Price Graph



Share Information

Code: KZA

Listing: ASX

52 week High Low
0.8 0.32

Sector: Pharma & Biotech

Website: www.kaziatherapeutics.com

Company Synopsis:

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) pipeline includes two clinical-stage drug development candidates.

action@proactiveinvestors.com

an unmet clinical need.

She said: "We urgently need to find better treatment options for these patients.

"We hope this study will help us identify a new treatment paradigm."

The study is expected to take about two years to complete and will be conducted under an "investigator IND" with the US FDA, where Alliance will assume primary regulatory responsibilities for the study.

Implementation of the study is conditional on approval from applicable institutional review boards and completion of contractual formalities, which have not yet been finalised.

Kazia anticipates patient recruitment will begin in the second half of this year.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).